JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.
Authors
- Konstantinos Leventakos (ORCID: https://orcid.org/0000-0001-9784-8603)
- Wen Wee Ma (ORCID: https://orcid.org/0000-0001-5899-4034)
- Daniel Morgensztern (ORCID: https://orcid.org/0000-0003-4349-2028)
- Yinxiang Wang
- Cunbo Ma
- Yanping Wang (ORCID: https://orcid.org/0009-0009-9498-2124)
- Chao Bi (ORCID: https://orcid.org/0000-0001-5895-1202)
- Jing Xiong (ORCID: https://orcid.org/0009-0000-2263-124X)
- Yiwei Lin (ORCID: https://orcid.org/0000-0003-1503-9082)
- Man Yan
- Di Kang
- Peng Wang
- Yuli Ding
- Xin Sun
Institutions
- Cleveland Clinic (US)
- Washington University in St. Louis (US)
- Jacobi Medical Center (US)
- Beijing VDJBio (China) (CN)
- SBI Pharmaceuticals (Japan) (JP)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3691
- Citations
- 3
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 2.42